My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

26.60 -0.33 (-1.23%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 18, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ACADIA Pharmaceuticals Inc. - Common Stock

< Previous 1 2

...

11 12 13 14 15 16 17 18 Next >

Analysts Try To See Beyond Acadia's Alzheimer's Disease Psychosis ↗

June 21, 2022

HC Wainwright says that a negative AdCom vote on Acadia Pharmaceuticals Inc&#

Via Benzinga

Why Is Acadia Pharmaceuticals (ACAD) Stock Down 33% Today? ↗

June 21, 2022

Today, investors in Acadia Pharmaceuticals and ACAD stock are in selling mode. The FDA gave a thumbs down on a key drug.

Via InvestorPlace

Nasdaq Rises 2.5%; ACADIA Pharmaceuticals Shares Plummet ↗

June 21, 2022

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining over 2.5% on Tuesday.

Via Benzinga

Dow Jumps 550 Points; Convey Health Solutions Shares Spike Higher ↗

June 21, 2022

U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 550 points on Tuesday.

Via Benzinga

45 Stocks Moving In Tuesday's Mid-Day Session ↗

June 21, 2022

Gainers Convey Health Solutions Holdings, Inc. (NYSE: CNVY) shares jumped 138.8% to $10.31 as the company agreed to be taken private by TPG Capital,.

Via Benzinga

U.S. Markets Open Higher; Lennar Earnings Top Views ↗

June 21, 2022

U.S. stocks traded higher this morning, with the Dow Jones gaining more than 500 points on Tuesday.

Via Benzinga

Acadia Pharmaceuticals Crashes After FDA Panel Votes Down Its Alzheimer's Psychosis Drug ↗

June 21, 2022

It's not looking good for Nuplazid in Alzheimer's disease psychosis.

Via Investor's Business Daily

The Daily Biotech Pulse: Thumbs Down For Acadia's Pimavanserin, Pfizer Buys Stake In Valneva, AstraZeneca - Ionis Eplontersen Aces Rare Disease Trial ↗

June 21, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Why Acadia Pharma Shares Are Plunging Today ↗

June 21, 2022

Via Benzinga

10 Biggest Price Target Changes For Tuesday ↗

June 21, 2022

Goldman Sachs cut SunPower Corporation. (NASDAQ: SPWR) price target from $19 to $13. SunPower shares fell 3.1% to $17.37 in pre-market trading.

Via Benzinga

Why ACADIA Pharmaceuticals Shares Are Trading Higher Today? ↗

June 15, 2022

Via Benzinga

Acadia Pharmaceuticals Announces Outcome of FDA Advisory Committee for NUPLAZID® (pimavanserin) for the Treatment of Alzheimer’s Disease Psychosis

June 17, 2022

From Acadia Pharmaceuticals Inc.

Via Business Wire

The Daily Biotech Pulse: Addex Terminates Parkinson's Study, Expanded Use Of Rhythm's Obesity Drug, FDA Approval For AbbVie's Skyrizi In Crohn's Disease ↗

June 17, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Acadia Pharmaceuticals Stock Trading Halted Today

June 17, 2022

From Acadia Pharmaceuticals Inc.

Via Business Wire

HC Wainwright Sees Opportunity For Acadia's Alzheimer's Candidate ↗

June 16, 2022

HC Wainwright says FDA's briefing document on ACADIA Pharmaceuticals Inc's (NASDAQ: ACAD) pimavanserin was not unexpected.

Via Benzinga

71 Biggest Movers From Yesterday ↗

June 16, 2022

Gainers Sidus Space, Inc. (NASDAQ: SIDU) shares jumped 225% to close at $4.68 on Wednesday after the company announced it is part of Collins Aerospace team which was awarded NASA's Exploration...

Via Benzinga

Why Acadia Pharma Surged Despite A Negative FDA Take On Its Lead Drug ↗

June 15, 2022

There were no surprises in the FDA's assessment of an Alzheimer's drug from Acadia Pharmaceuticals, and ACAD stock surged Wednesday.

Via Investor's Business Daily

55 Stocks Moving In Wednesday's Mid-Day Session ↗

June 15, 2022

Gainers Sidus Space, Inc. (NASDAQ: SIDU) shares surged 92.4% to $2.77 after the company announced it is part of Collins Aerospace team which was awarded NASA's Exploration Extravehicular Activity...

Via Benzinga

5 Biotech Stocks To Watch During The Week Of June 13 ↗

June 13, 2022

Biotech stocks continued to be under pressure in the past week amid broader market weakness, precipitated by economic worries. Company-specific developments also triggered downward moves. Here's a...

Via Benzinga

6 Biotech Stocks to Buy Now Ahead of These June Catalysts ↗

June 03, 2022

These biotech stocks face some key make-or-break events in June that could have big implication for their futures.

Via InvestorPlace

Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates ↗

May 31, 2022

May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. New molecular entity approvals, an indicator of innovation in drug research, totaled three during the month,...

Via Benzinga

This Biotech Looks Good With Increased M&A activity ↗

May 20, 2022

Fierce Biotech backs this up: “Biopharmas have $1.7 trillion to spend on deals this year, and big players like Novartis, Pfizer and Merck & Co. have made it pretty clear they’re on the hunt for...

Via Talk Markets

ACADIA Pharmaceuticals's Return On Capital Employed Insights ↗

May 18, 2022

ACADIA Pharmaceuticals (NASDAQ:ACAD) brought in sales totaling $115.47 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 162.35%, resulting in a loss of $113.06...

Via Benzinga

ACADIA Pharmaceuticals: Q1 Earnings Insights ↗

May 04, 2022

ACADIA Pharmaceuticals (NASDAQ:ACAD) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

Via Benzinga

Acadia Pharmaceuticals Reports First Quarter 2022 Financial Results

May 04, 2022

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals to Present at Upcoming Investor Conferences

May 03, 2022

From Acadia Pharmaceuticals Inc.

Via Business Wire

ACADIA Pharmaceuticals's Earnings Outlook ↗

May 03, 2022

ACADIA Pharmaceuticals (NASDAQ:ACAD) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs ↗

May 03, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Acadia Pharmaceuticals Announces FDA Advisory Committee Meeting to Review Resubmission of Supplemental New Drug Application for NUPLAZID® (pimavanserin) for the Treatment of Alzheimer’s Disease Psychosis Scheduled for June 17, 2022

May 02, 2022

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals to Announce First Quarter 2022 Financial Results on May 4, 2022

April 21, 2022

From Acadia Pharmaceuticals Inc.

Via Business Wire

< Previous 1 2

...

11 12 13 14 15 16 17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.